Organ-sparing treatment for early rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a newer approach can treat early-stage rectal cancer without removing the whole rectum, aiming to preserve bowel function. It compares different treatment options to see which is safest and most effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rectal cancer confirmed by biopsy that has not spread to lymph nodes or other organs.
- Your tumor is located within 12 cm of the anus and is small (less than 4 cm).
- You are generally healthy (able to do normal activities with little or no help).
- You have not had previous radiation to the pelvis, and you are not pregnant or breastfeeding.
- You do not have certain genetic conditions (like DPYD deficiency or Gilbert's syndrome) that could make treatment unsafe.
- Your medical team has agreed that both standard surgery and chemoradiation are possible options for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
This trial tests whether some people with locally advanced rectal cancer can safely avoid surgery after chemoradiotherapy. If the tumor disappears, patients may be monitored closely instead of having an operation, which could help preserve the anus.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial tests if a newer chemo pill (TAS-102) works better than the standard pill (capecitabine) when given before radiation and surgery for rectal cancer. It is for people with stage II or III rectal cancer that has certain high-risk features.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.